VistaGen Therapeutics, Inc.
VTGN
$2.26
-$0.11-4.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 27.87% | 117.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 27.87% | 117.86% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 27.87% | 117.86% | |||
| SG&A Expenses | -3.48% | -8.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.55% | 17.97% | |||
| Operating Income | -6.28% | -17.28% | |||
| Income Before Tax | -8.76% | -20.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.70% | -20.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.70% | -20.76% | |||
| EBIT | -6.28% | -17.28% | |||
| EBITDA | -6.28% | -17.30% | |||
| EPS Basic | -8.41% | -20.64% | |||
| Normalized Basic EPS | -8.48% | -20.57% | |||
| EPS Diluted | -8.41% | -20.64% | |||
| Normalized Diluted EPS | -8.48% | -20.57% | |||
| Average Basic Shares Outstanding | 0.26% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||